Vie Ventures Launches Groundbreaking Therapeutics Council to Tackle Autoimmune Diseases

Vie Ventures, a pioneering life sciences investment firm, recently announced the convening of its inaugural Therapeutics Advisory Council (TAC) aimed at enhancing collaboration across the autoimmune disease sector. Held on September 9, 2025, in the vibrant city of New York, this significant event gathered key stakeholders including leaders from philanthropy, the biotechnology industry, and venture capital, all united in their mission to transform the landscape of autoimmune and inflammatory disease treatments.

The TAC serves as a dynamic coalition where foundations and investors work collaboratively to identify shared biological insights and mitigate risks associated with therapeutic development. With the objective of accelerating cures for autoimmune disorders, this council represents a unified response to the challenges faced within this complex field.

Alongside the event's kick-off, Vie Ventures welcomed additional strategic collaborators to its network, expanding its coalition to over ten prominent disease-focused organizations. Newly joined members include the American Diabetes Association, Arthritis Foundation, Beyond Celiac, Food Allergy Fund, Immune Boost Capital, and the National Psoriasis Foundation. These esteemed organizations join existing members such as the Crohn's & Colitis Foundation and Lupus Research Alliance, each contributing extensive expertise, patient networks, and robust research infrastructure tailored to autoimmune diseases.

Dr. Steven St. Peter, Co-Founder and Managing Director of Vie Ventures, expressed the vision behind the TAC, stating, "We launched the Therapeutics Advisory Council to create a forum where foundations, industry innovators, and investors can work side by side to accelerate progress in autoimmune disease." His sentiment resonates with the council's collective goal of fostering a collaborative environment that addresses shared challenges and explores opportunities for growth in therapeutic advancements.

A key highlight of the inaugural meeting was the scientific discussion centered on "Fibrosis Across Autoimmune Diseases." This session emphasized the significant implications of fibrosis as a common pathway in multiple autoimmune conditions, underlining the need for reliable biomarkers, clinical endpoints, and innovative anti-fibrotic therapies, which currently remain largely unapproved. The discussion reinforced the importance of cross-disease collaboration, showcasing how collective expertise can expedite drug development by leveraging shared knowledge and data among various indications.

The afternoon panel further delved into the funding landscape for discovery research, featuring experts from academia, finance, and the pharmaceutical industry. Reflecting on the current state of biomedical innovation, the panel identified challenges related to U.S. research funding and market pressures. With capital scarcity and heightened investor caution influencing company formation and financing strategies, the discussion highlighted the potential for new funding mechanisms that align with Big Pharma's commitment to innovation.

As the day drew to a close, a gathering of CEOs and senior leaders from disease philanthropy focused on shared insights and reflections from the event. Their discussions underscored the opportunity to utilize common infrastructure such as biorepositories and trial networks, as well as the hurdles of disease heterogeneity and diagnostic gaps. This concluding dialogue fostered a sense of collaboration and momentum, reinforcing the commitment to jointly advance breakthroughs in therapies for autoimmune diseases.

About the Therapeutics Advisory Council

The Therapeutics Advisory Council was established by Vie Ventures to serve as a structured platform for collaboration among disease-focused philanthropies, scientists, and investors. This initiative is designed to unite diverse stakeholders in the quest to advance treatments for autoimmune and immune-mediated diseases. Learn more about Vie Ventures and their initiatives at vieventures.com.

About Vie Ventures

Operating at the intersection of venture capital and disease philanthropy, Vie Ventures is dedicated to investing in the development of novel therapeutics targeting autoimmune diseases and other immune disorders. With a wealth of expertise and a strong commitment to equitable health outcomes, Vie Ventures aims to catalyze transformative advancements in patient care. Discover more through their website at vieventures.com.